메뉴 건너뛰기




Volumn 12, Issue 8, 2012, Pages 995-1004

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice

Author keywords

DPP 4 inhibitor; Inflammation; Insulin sensitivity; Islet function; Islet morphology; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; BI 38335; CELL MARKER; GLUCOSE; HEMOGLOBIN A1C; KI 67 ANTIGEN; LINAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

EID: 84866540801     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412802480970     Document Type: Article
Times cited : (41)

References (44)
  • 1
    • 0033842027 scopus 로고    scopus 로고
    • Interactions between insulin resistance and insulin secretion in the development of glucose intolerance
    • Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-33.
    • (2000) J Clin Invest , vol.106 , pp. 329-333
    • Cavaghan, M.K.1    Ehrmann, D.A.2    Polonsky, K.S.3
  • 2
    • 0035856943 scopus 로고    scopus 로고
    • Diabetes mellitus and genetically programmed defects in [beta]-cell function
    • Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in [beta]-cell function. Nature 2001; 414: 788-91.
    • (2001) Nature , vol.414 , pp. 788-791
    • Bell, G.I.1    Polonsky, K.S.2
  • 3
    • 0038707331 scopus 로고    scopus 로고
    • Selective SS-cell loss and---cell expansion in patients with type 2 diabetes mellitus in Korea
    • Yoon KH, Ko SH, Cho JH, et al. Selective SS-cell loss and---cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-8.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 2300-2308
    • Yoon, K.H.1    Ko, S.H.2    Cho, J.H.3
  • 4
    • 33845866857 scopus 로고    scopus 로고
    • Inflammation and metabolic disorders
    • Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
    • (2006) Nature , vol.444 , pp. 860-867
    • Hotamisligil, G.S.1
  • 5
    • 18244370762 scopus 로고    scopus 로고
    • Inflammation, stress, and diabetes
    • Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
    • (2005) J Clin Invest , vol.115 , pp. 1111-1119
    • Wellen, K.E.1    Hotamisligil, G.S.2
  • 6
    • 0030061922 scopus 로고    scopus 로고
    • IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-ii-and obesity-induced insulin resistance
    • Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-ii-and obesity-induced insulin resistance. Science 1996; 271: 665-70.
    • (1996) Science , vol.271 , pp. 665-670
    • Hotamisligil, G.S.1    Peraldi, P.2    Budavari, A.3
  • 8
    • 70449394029 scopus 로고    scopus 로고
    • Pancreatic islet inflammation in type 2 diabetes: From yyyand aaacell compensation to dysfunction
    • Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: From yyyand aaacell compensation to dysfunction. Arch Physiol Biochem 2009; 115: 240-7.
    • (2009) Arch Physiol Biochem , vol.115 , pp. 240-247
    • Ehses, J.A.1    Ellingsgaard, H.2    Boni-Schnetzler, M.3    Donath, M.Y.4
  • 9
    • 33748331194 scopus 로고    scopus 로고
    • Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
    • Mu J, Woods J, Zhou Y-P, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
    • (2006) Diabetes , vol.55 , pp. 1695-1704
    • Mu, J.1    Woods, J.2    Zhou, Y-P.3
  • 10
    • 0033513455 scopus 로고    scopus 로고
    • Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
    • Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
    • (1999) Diabetes , vol.48 , pp. 2270-2276
    • Xu, G.1    Stoffers, D.A.2    Habener, J.F.3    Bonner-Weir, S.4
  • 11
    • 57349099271 scopus 로고    scopus 로고
    • Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-Oxopentyl)-N-[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-l-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes
    • Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-Oxopentyl)-N-[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-l-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 2008; 327: 683-91.
    • (2008) J Pharmacol Exp Ther , vol.327 , pp. 683-691
    • Cheng, Q.1    Law, P.K.2    de Gasparo, M.3    Leung, P.S.4
  • 12
    • 0036583164 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
    • Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-75.
    • (2002) Diabetes Care , vol.25 , pp. 869-875
    • Ahrén, B.1    Simonsson, E.2    Larsson, H.3
  • 13
    • 37149006184 scopus 로고    scopus 로고
    • Management of type 2 diabetes in treatment-naive elderly patients
    • Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 2007; 30: 3017-22.
    • (2007) Diabetes Care , vol.30 , pp. 3017-3022
    • Pratley, R.E.1    Rosenstock, J.2    Pi-Sunyer, F.X.3
  • 14
    • 37349073397 scopus 로고    scopus 로고
    • 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
    • Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-53.
    • (2007) J Med Chem , vol.50 , pp. 6450-6453
    • Eckhardt, M.1    Langkopf, E.2    Mark, M.3
  • 15
    • 59649105751 scopus 로고    scopus 로고
    • Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356[(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models
    • Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356[(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-3.
    • (2009) J Pharmacol Exp Ther , vol.328 , pp. 553-556
    • Thomas, L.1    Tadayyon, M.2    Mark, M.3
  • 16
    • 41149118550 scopus 로고    scopus 로고
    • (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
    • Thomas L, Eckhardt M, Langkopf E, et al.(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-182.
    • (2008) J Pharmacol Exp Ther , vol.325 , pp. 175-182
    • Thomas, L.1    Eckhardt, M.2    Langkopf, E.3
  • 17
    • 0026761361 scopus 로고
    • Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter
    • Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol Renal Physiol 1992; 263: F459-F65.
    • (1992) Am J Physiol Renal Physiol , vol.263
    • Wells, R.G.1    Pajor, A.M.2    Kanai, Y.3
  • 18
    • 0028044629 scopus 로고
    • The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for Dglucose
    • Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for Dglucose. J Clin Invest 1994; 93: 397-404.
    • (1994) J Clin Invest , vol.93 , pp. 397-404
    • Kanai, Y.1    Lee, W.S.2    You, G.3    Brown, D.4    Hediger, M.A.5
  • 19
    • 52649083832 scopus 로고    scopus 로고
    • Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
    • Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76.
    • (2008) J Pharmacol Exp Ther , vol.327 , pp. 268-276
    • Fujimori, Y.1    Katsuno, K.2    Nakashima, I.3
  • 20
    • 33845873376 scopus 로고    scopus 로고
    • Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
    • Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-30.
    • (2007) J Pharmacol Exp Ther , vol.320 , pp. 323-330
    • Katsuno, K.1    Fujimori, Y.2    Takemura, Y.3
  • 21
    • 67349275999 scopus 로고    scopus 로고
    • Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
    • Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-19.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 513-519
    • Komoroski, B.1    Vachharajani, N.2    Feng, Y.3
  • 22
    • 33746588255 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
    • Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29: 1963-72.
    • (2006) Diabetes Care , vol.29 , pp. 1963-1972
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 23
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus
    • for the UKPDSG
    • Turner RC, Cull CA, Frighi V, Holman RR, for the UKPDSG. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA 1999; 281: 2005-12.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 24
    • 78650720971 scopus 로고    scopus 로고
    • Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time?
    • Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011; 124: S19-S34.
    • (2011) Am J Med , vol.124
    • Zinman, B.1
  • 25
    • 84858212683 scopus 로고    scopus 로고
    • Sodium glucose co transporter 2 (SGLT2) inhibitors: A new sword for the treatment of type 2 diabetes mellitus
    • Rajesh R, Naren P, Vidyasagar S, et al. Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus. Int J Pharm Sci Res 2010; 1: 139-47.
    • (2010) Int J Pharm Sci Res , vol.1 , pp. 139-147
    • Rajesh, R.1    Naren, P.2    Vidyasagar, S.3
  • 26
    • 78649691630 scopus 로고    scopus 로고
    • Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    • Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 65-74
    • Taskinen, M.R.1    Rosenstock, J.2    Tamminen, I.3
  • 27
    • 79953044464 scopus 로고    scopus 로고
    • Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes
    • Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabetic Med 2010; 27: 1409-19.
    • (2010) Diabetic Med , vol.27 , pp. 1409-1419
    • Forst, T.1    Uhlig-Laske, B.2    Ring, A.3
  • 28
    • 33644781780 scopus 로고    scopus 로고
    • Angiotensin II type 1 receptor blockade improves 11-cell function and glucose tolerance in a mouse model of type 2 diabetes
    • Chu KY, Lau T, Carlsson P-O, Leung PS. Angiotensin II type 1 receptor blockade improves 11-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367-74.
    • (2006) Diabetes , vol.55 , pp. 367-374
    • Chu, K.Y.1    Lau, T.2    Carlsson, P-O.3    Leung, P.S.4
  • 29
    • 0030942255 scopus 로고    scopus 로고
    • Proliferation and differentiation in the human fetal endocrine pancreas
    • Bouwens L, Lu WG, De Krijger R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia 1997; 40: 7.
    • (1997) Diabetologia , vol.40 , pp. 7
    • Bouwens, L.1    Lu, W.G.2    de Krijger, R.3
  • 30
    • 69549098032 scopus 로고    scopus 로고
    • IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
    • Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009: 106(33): 13998-4003.
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.33 , pp. 13998-14003
    • Ehses, J.A.1    Lacraz, G.2    Giroix, M.H.3
  • 31
    • 33748306069 scopus 로고    scopus 로고
    • Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat
    • Homo-Delarche F, Calderari S, Irminger J-C, et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006; 55: 1625-33.
    • (2006) Diabetes , vol.55 , pp. 1625-1633
    • Homo-Delarche, F.1    Calderari, S.2    Irminger, J-C.3
  • 32
    • 1542374750 scopus 로고    scopus 로고
    • Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets
    • Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.
    • (2004) Diabetologia , vol.47 , pp. 240-248
    • Lau, T.1    Carlsson, P.O.2    Leung, P.S.3
  • 33
    • 0036724346 scopus 로고    scopus 로고
    • Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women
    • Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes 2002; 51: 2796-2803.
    • (2002) Diabetes , vol.51 , pp. 2796-2803
    • Buchanan, T.A.1    Xiang, A.H.2    Peters, R.K.3
  • 34
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-53.
    • (1998) The Lancet , vol.352 , pp. 837-853
    • Group, U.P.D.S.U.1
  • 35
    • 52249109319 scopus 로고    scopus 로고
    • New combination treatments in the management of diabetes: Focus on sitagliptin-metformin
    • Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008; 4: 9.
    • (2008) Vasc Health Risk Manag , vol.4 , pp. 9
    • Green, J.1    Feinglos, M.2
  • 36
    • 77956744479 scopus 로고    scopus 로고
    • Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: A prospective randomized double-blind clinical trial
    • Ruggenenti P, Cattaneo D, Rota S, et al. Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 2010: 33(9): 1954-6.
    • (2010) Diabetes Care , vol.33 , Issue.9 , pp. 1954-1956
    • Ruggenenti, P.1    Cattaneo, D.2    Rota, S.3
  • 37
    • 65449135058 scopus 로고    scopus 로고
    • Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: A 54-week study
    • Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-83.
    • (2009) Curr Med Res Opin , vol.25 , pp. 569-583
    • Williams-Herman, D.1    Johnson, J.2    Teng, R.3
  • 38
    • 84866529981 scopus 로고    scopus 로고
    • The DPP-4 inhibitor linagliptin significantly improves insulin sensitivity in diet induced obese mice
    • Kern M KN, Klein T, Mark M, Blüher M. The DPP-4 inhibitor linagliptin significantly improves insulin sensitivity in diet induced obese mice. Diabetes 2010; (Suppl 1) 59: A577.
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Kern, M.K.N.1    Klein, T.2    Mark, M.3    Blüher, M.4
  • 39
    • 71949118923 scopus 로고    scopus 로고
    • Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I
    • Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-29.
    • (2009) Endocrinology , vol.150 , pp. 5218-5229
    • Boni-Schnetzler, M.1    Boller, S.2    Debray, S.3
  • 40
    • 0036738398 scopus 로고    scopus 로고
    • Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
    • Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 10.
    • (2002) J Clin Invest , vol.110 , pp. 10
    • Maedler, K.1    Sergeev, P.2    Ris, F.3
  • 41
    • 0043168062 scopus 로고    scopus 로고
    • Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells
    • Vives-Pi M, Somoza N, FernÁNdez-Alvarez J, et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 2003; 133: 208-18.
    • (2003) Clin Exp Immunol , vol.133 , pp. 208-218
    • Vives-Pi, M.1    Somoza, N.2    FernÁNdez-Alvarez, J.3
  • 42
    • 44849125877 scopus 로고    scopus 로고
    • Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways
    • De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J Immunol 2008; 180: 4308-15.
    • (2008) J Immunol , vol.180 , pp. 4308-4315
    • de Filippo, K.1    Henderson, R.B.2    Laschinger, M.3    Hogg, N.4
  • 43
    • 79952404360 scopus 로고    scopus 로고
    • SGLT2 deletion improves glucose homeostasis and preserves pancreatic-cell function
    • Jurczak MJ, Lee H-Y, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic-cell function. Diabetes 2011; 60: 890-8.
    • (2011) Diabetes , vol.60 , pp. 890-898
    • Jurczak, M.J.1    Lee, H-Y.2    Birkenfeld, A.L.3
  • 44
    • 12944331141 scopus 로고    scopus 로고
    • Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats
    • Yang BC, Brown KK, Chen LH, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 18(4): 23.
    • (2004) BMC Pharmacol , vol.18 , Issue.4 , pp. 23
    • Yang, B.C.1    Brown, K.K.2    Chen, L.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.